Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Disparities

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

In 2021, the age-standardised rates for ADOD were 694.01 (95% uncertainty intervals [UIs]: 602.88 to 794.08) for prevalence, 119.76 (95% UI: 104.96 to 135.89) for incidence, and 481.70 (95% UI: 228.79 to 1,023.96) for disability-adjusted life years (DALYs). Females exhibited a higher ADOD burden than males across all age groups, with an age-standardised prevalence rate of 769.94 (95% UI: 670.71 to 877.57) in females compared to 589.47 (95% UI: 507.48 to 678.79) in males. The slope inequality index of crude DALY rate increased from 315.23 (95% confidence intervals [CIs]: 310.43 to 437.87) in 1990 to 758.29 (95% CI: 692.48 to 908.29) in 2021 at the country level. The Lorenz curves for the crude DALY rate of ADOD in 1990 and 2021 lay below the equality line, indicating a higher burden among countries and territories with a higher socio-demographic index (SDI) ranking. By 2046, global prevalence is projected to reach 124.89 million, a 119.67% increase from 2021. The ADOD burden has increased globally, with significant regional disparities. Urgent action is required to prevent ADOD, especially among females and in high-SDI regions.

What this study adds

Evidence grade: Moderate

This global analysis found that the burden of Alzheimer's disease and other dementias increased from 1990 to 2021, with females carrying a higher burden than males across all age groups. Reported effect size: 119.67%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Hu, M., Wang, T., Song, J., Liu, N., Zeng, Y., Hu, D., et al. (2025). Global, Regional, and National Disparities in the Burden of Alzheimer’s Disease and Other Dementias, 1990–2021. Neuroepidemiology. https://doi.org/10.1159/000549854

Vancouver

Hu M, Wang T, Song J, Liu N, Zeng Y, Hu D, et al. Global, Regional, and National Disparities in the Burden of Alzheimer’s Disease and Other Dementias, 1990–2021. Neuroepidemiology. 2025. doi:10.1159/000549854. PMID: 41417684.

BibTeX

@article{hu2025-41417684,
  author  = {Hu, Meiling and Wang, Tongyun and Song, Jing and Liu, Ningrui and Zeng, Yuhong and Hu, Danqing and Guo, Yang and Chang, Jie and others},
  title   = {{Global, Regional, and National Disparities in the Burden of Alzheimer’s Disease and Other Dementias, 1990–2021}},
  journal = {Neuroepidemiology},
  year    = {2025},
  doi     = {10.1159/000549854},
  pmid    = {41417684},
  url     = {https://doi.org/10.1159/000549854}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This global analysis found that the burden of Alzheimer's disease and other dementias increased from 1990 to 2021, with females carrying a higher burden than males across all age groups. It projects global prevalence will reach 124.89 million by 2046 and calls for urgent action, especially among females and in high-SDI regions.

Study details

How this study scored 41/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 1 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 41 of 100.41 of 100 points earned59 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Neuroepidemiology)
Journal's citation record 1 / 4 Neuroepidemiology: journal h-index 125 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 3 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.0 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 1.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Zhennan Lin: h-index 7 (OpenAlex, whole career)
Institution's track record 3 / 3 University of Washington: institution h-index 3,540 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 14 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41417684)
Free to read 0 / 2 Behind a paywall — scores zero
Total 41 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Disparities from nearby years

Also in Disparities

98 studies in the library are filed under Disparities with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Disparities hub.

Similar studies

More on Disparities

See all studies in Disparities →